Paulo Fontoura
Physician‑scientist and drug‑development leader in neuroscience
Summary
Work
Education
Projects
Writing
Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open‑label extension of the PASADENA trial
October 1, 2024Exploratory analysis comparing long‑term motor progression in prasinezumab‑treated PASADENA participants versus an external PPMI comparator cohort, suggesting slower motor progression over 4 years.
Safety and efficacy of olesoxime in patients with type 2 or non‑ambulatory type 3 spinal muscular atrophy: a randomised, double‑blind, placebo‑controlled phase 2 trial
January 1, 2017Phase 2 randomized, placebo‑controlled trial evaluating olesoxime in type 2 and non‑ambulatory type 3 SMA assessing motor function outcomes over 24 months.
Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges
January 1, 2010Review of the development, promise and safety challenges of monoclonal antibody therapies for multiple sclerosis, discussing efficacy, risks such as PML, and monitoring strategies.
A Single Dose, Randomized, Controlled Proof‑Of‑Mechanism Study of RG7713 (a V1a receptor antagonist) in High‑Functioning Adults with Autism Spectrum Disorder
Randomized, double‑blind, placebo‑controlled crossover study assessing behavioral and biomarker effects of a V1a receptor antagonist (RG7713) in adult males with high‑functioning ASD; reported exploratory improvements in social‑cognitive biomarkers.